

**PCT**WORLD INTELLECTUAL PROPERTY  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER

WO 9606598A1

(51) International Patent Classification <sup>6</sup> : <b>A61K 9/08, 47/14</b>		A1	(11) International Publication Number: <b>WO 96/06598</b>
			(43) International Publication Date: 7 March 1996 (07.03.96)
<p>(21) International Application Number: PCT/US95/10469</p> <p>(22) International Filing Date: 16 August 1995 (16.08.95)</p> <p>(30) Priority Data: 08/296,778      26 August 1994 (26.08.94)      US</p> <p>(71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).</p> <p>(72) Inventors: FU LU, Mou-Ying; 195 Grafton Court, Lake Bluff, IL 60044 (US). ADJEI, Akwete, L.; 38770 Red Oak Terrace, Wadsworth, IL 60083 (US). GUPTA, Pramod, K.; 6986 Bennington Drive, Gurnee, IL 60031 (US).</p> <p>(74) Agents: BRAINARD, Thomas, D. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).</p>			<p>(81) Designated States: AU, CA, JP, KR, MX, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p><b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: AEROSOL DRUG FORMULATIONS CONTAINING POLYGLYCOLYZED GLYCERIDES</p> <p>(57) Abstract</p> <p>Pharmaceutical compositions for aerosol delivery comprising (a) a medicament, (b) a non-chlorofluorocarbon propellant, and (c) a polyglycolyzed glyceride or a pharmaceutically acceptable derivative thereof, as well as a method for preparing such compositions in which unwanted aggregation of the medicament is prevented without the use of surfactants, protective colloids or cosolvents.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LV	Latvia	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

## AEROSOL DRUG FORMULATIONS CONTAINING POLYGLYCOLYZED GLYCERIDES

The present invention relates to drug formulations for aerosol delivery which are compatible with non-chlorofluorocarbon propellants, and especially to excipients which are useful therein. In particular, the invention relates to inhalable formulations comprising polyglycolyzed glycerides, which formulations possess a variety of advantageous properties.

### Background of the Invention

Numerous pharmaceutical compounds are preferentially delivered by means of metered dose inhalation (MDI) devices, in which a physiologically inert propellant of high vapor pressure is used to discharge a precise amount of medication with each operation. These MDI devices, also known as aerosols or inhalers, have found widespread use among patients suffering, for example, from episodic or chronic asthma. The propellants of choice have historically been chlorofluoro-carbons, such as Propellant 11 (trichlorofluoromethane), Propellant 12 (dichlorodifluoromethane) and Propellant 114 (dichlorotetrafluoroethane).

In recent years, however, there have been growing concerns that chlorofluorocarbon (CFC) propellants have detrimental environmental effects, and in particular that they interfere with the protective upper-atmosphere ozone layer. Under an international accord (the Montreal Protocol), the use of CFC propellants will be prohibited by the start of the year 2000, and possibly sooner. Alternative propellant vehicles are being developed which exhibit little or no ozone depletion potential (ODP). Such alternative propellants include two -- HFC-134a (1,1,1,2-tetrafluoroethane) and HFC-227ea (1,1,1,2,3,3,3-heptafluoropropane) -- which have negligible ODP and are currently undergoing safety and environmental testing.

Unfortunately, many surfactants which are generally used in known MDI formulations have been found to be immiscible, and therefore incompatible, with these new, non-CFC propellants. Such surfactants are necessary to prevent aggregation (in the form of "caking" or crystallization, for example) of the medicinally active compound in the reservoir of the inhaler, to facilitate uniform dosing upon aerosol administration, and to provide an aerosol spray discharge having a favorable respirable fraction (that is, a particle size distribution such that a large portion of the discharge reaches the alveoli where absorption takes place, and thus produces high lung deposition efficiencies). To overcome this incompatibility, it has previously been taught to include cosolvents (such as ethanol) with the non-CFC propellants so as to blend the surfactants into the formulation. Another suggested approach has been to emulsify the MDI formulation in the presence of a surfactant with low-vapor pressure additives, such as polyhydroxy alcohols as for example propylene glycol.

Such cosolvents or additives may of course be physiologically active, and in some instances may not be tolerated by the user of an MDI medication. There is therefore a need for MDI formulations compatible with non-CFC, non-ozone depleting propellants, which prevent aggregation of drug particles without the use of cosolvents or similar carrier additives, and which provide uniformity of dosing and a favorable respirable fraction.

Surprisingly, it has now been found that polyglycolized glycerides, as for example Labrafac® CM 6, Labrafil® WL 2609 BS, Labrafac® CM 8, Labrafac® CM 10, Labrafil® M 10, Labrafil® NA 10, Labrafac® CM 12, Labrasol® (Labrafac® CM 14) and the like are capable of stabilizing MDI formulations utilizing non-ozone depleting propellants such as HFC-134a and HFC-227ea so as to (i) prevent aggregation, (ii) provide dosing uniformity, and (iii) afford high lung deposition efficiency without the need for either surfactants or cosolvents. Additionally, the polyglycolized glycerides have the unexpected benefit of providing adequate lubrication for the valve used in an MDI product without the need for additional lubricants, thus aiding reliable functioning of the aerosol device throughout the life of the product.

Significant characteristics of such polyglycolized glycerides used are that: (i) they are non-ionic surface active agents which do not chemically interact with drug; (ii) they have been used previously in oral drug delivery liquid dosage form, thereby establishing their physiological acceptability; (iii) their hydrophilic lipophilic balance (HLB) values are much higher than sorbitan trioleate (SPAN 85), ranging in the case of Labrafac® from 6 to 14 and in the case of Labrafil® products of interest from 6 to 10 (compared to 4 for SPAN 85); and (iv) they are highly soluble in HFC 134a. Non-CFC formulations which include polyglycolized glycerides do not require the addition of (i) cosolvents like ethanol to blend the surfactant into the formulation, (ii) conventional surfactants such as sorbitan trioleate (SPAN 85), sorbitan monooleate and oleic acid, or (iii) protective colloids like sodium lauryl sulfate, cholesterol and palmitic acid, yet provide high lung deposition efficiencies and respirable fractions comparable to those obtained with known CFC-propellant formulations. It is thus expected that non-CFC formulations comprising polyglycolized glycerides will be useful for the delivery of both peptide and non-peptide pharmaceutical medicaments for which MDI delivery is deemed preferable.

#### Brief Description of the Drawings

Figure 1 illustrates the drug content uniformity of formulations of the present invention containing cyclosporin A (25 mg/mL) and Labrafac® in the propellant HFC-134a.

Figure 2 illustrates dosimetry reproducibility of formulations of the present invention containing cyclosporin A (25 mg/mL) and Labrafac® (3 mg/mL) in the propellant HFC-134a.

Figure 3 illustrates particle size distribution obtained using a formulation of the present invention containing leuprolide (10 mg/mL) and 0.2% Labrafac® CM 10 and 0.05% aspartame.

## 5 Summary of the Invention

According to one aspect of the present invention, pharmaceutical compositions are disclosed which are useful for aerosol delivery, as for example by inhalation and pulmonary absorption, comprising a therapeutically effective amount of a medicament, a non-chlorofluorocarbon propellant, and a polyglycolized glyceride such as Labrafac® CM 6, Labrafil® WL 2609 BS, Labrafac® CM 8, Labrafac® CM 10, Labrafil® M 10, Labrafil® NA10, Labrafac® CM 12 or Labrasol® (Labrafac® CM 14). The compositions may optionally comprise a sweetener such as Nutrasweet® (aspartame) an/or a taste-masking agent such as menthol. The propellants in such compositions are preferably fluorocarbons and, more preferably, non-ozone depleting fluorocarbons such as HFC-134a or HFC-227ea. The medicaments to be delivered are preferably LHRH analogs, 5-lipoxygenase inhibitors, immunosuppressants or bronchodilators; especially preferred medicaments include leuprolide acetate, the LHRH antagonist Ac-D-2-Nal-D-4-Cl-Phe-D-3-Pal-Ser-N-MeTyr-D-Lys(Nic)-Leu-Lys(N-Isp)-Pro-D-Ala-NH<sub>2</sub> (hereinafter "D-2-Nal"), the 5-lipoxygenase inhibitor N-[3-[5-(4-fluorophenylmethyl)-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea, the immunosuppressant cyclosporin A, and the adrenergic bronchodilators isoproterenol and albuterol. (As used herein, the terms "5-lipoxygenase inhibitor" or "5-LO inhibitor" refer to any physiologically active compound capable of affecting leukotriene biosynthesis.)

The polyglycolized glycerides used in the present invention may be present in a concentration of between about 0.001% and about 10% by weight, preferably in a concentration of between about 0.002% and about 5% by weight and more preferably in a concentration of between 0.01% and about 1%.

A sweetener such as aspartame and/or a taste-masking agent such as menthol may also be present in concentrations of between about 0.0001% and about 10% each by weight.

Particularly preferred pharmaceutical compositions embodying the present invention include those comprising leuprolide acetate in a concentration of between 0.05% and 5% by weight, Labrafac® in a concentration of between 0.01% and 1% by weight, aspartame in a concentration of between 0.02% and 0.5% by weight, and menthol in a concentration of between 0.01 and 0.25% by weight.

Especially preferred pharmaceutical compositions embodying the present invention are those comprising leuprolide acetate in a concentration of between 0.125% and 0.5% by weight, Labrafac® in a concentration of between 0.1% and 0.5% by weight, aspartame in a

concentration of between 0.05% and 0.2% by weight, and menthol in a concentration of between 0.025 and 0.1% by weight.

Alternative, especially preferred pharmaceutical compositions embodying the present invention are those comprising leuprolide acetate in a concentration of between 0.5% and 2% by weight, Labrafac® in a concentration of between 0.2% and 1% by weight, aspartame in a concentration of about 0.1% by weight, and menthol in a concentration of about 0.05% by weight.

In a further aspect of the present invention is disclosed a method of preparing a stable suspension of particles of a medicament in a liquid phase non-chlorofluorocarbon aerosol propellant, which method comprises (a) combining the medicament, the propellant, and a polyglycolized glyceride in an amount sufficient to prevent aggregation of the particles to form a mixture and (b) agitating the mixture to completely blend the various components. (The order of addition may alternatively be varied so that the medicament and the polyglycolized glyceride, or the propellant and the polyglycolized glyceride, or the medicament and the propellant are first mixed prior to addition of the third component.) Preferably, the polyglycolized glyceride may be added in an amount of between about 0.001% and about 5% by weight; more preferably, the polyglycolized glyceride may be added in an amount of between about 0.01% and about 1% by weight. The propellants, medicaments and polyglycolized glycerides suitable for use in the method of the present invention are those described above in connection with the pharmaceutical compositions of this invention.

#### Detailed Description of the Invention

It is expected that numerous non-ozone depleting aerosol propellants may be used with the compositions and methods of the present invention. These include not only HFC-134a and HFC-27ea, described above, but also halogenated alkanes in general, such as HCFC-123 (1,1,1-trifluoro-2,2-dichloroethane), HCFC-124 (1,1,1,2-tetrafluorochloroethane), HCFC-141b, HCFC-225, HFC-125, FC-C51-12 (perfluorodimethylcyclobutane), DYMEL A (dimethyl ether) and DYMEL 152a (1,1-difluoroethane). The preferred propellants are HFC-134a and HFC-27ea, HFC-134a being especially preferred.

The term "polyglycolized glyceride" as used herein refers to specific mixtures of mono, di and triglycerides and polyethylene glycol mono and diesters, obtained either by partial alcoholysis of hydrogenated vegetable oils using polyethylene glycol of relative molecular weight ranging from about 200 to about 2000, or by esterification of fatty acids using polyethylene glycol of relative molecular weight ranging from about 200 to about 2000

and glycerol. The polyglycolyzed glycerides of the present invention have Hydrophilic Lipophilic Balance (HLB) values of between and including 6 and 14. The free glycerol content is less than 3%. Examples of suitable polyglycolyzed glycerides include Labrafac® CM 6, Labrafil® WL 2609 BS, Labrafac® CM 8, Labrafac® CM 10, Labrafil® M 10, Labrafil® NA10, Labrafac® CM 12, Labrasol® (Labrafac® CM 14) and the like.

Examples of polyglycolyzed glycerides include Labrafac® CM 6, Labrafil® WL 2609 BS, Labrafac® CM 8, Labrafac® CM 10, Labrafil® M 10, Labrafil® NA10, Labrafac® CM 12, and Labrasol® (Labrafac® CM 14). Preferred polyglycolyzed glycerides having HLB values of between 6 and 14, inclusive, and containing medium chain (C<sub>8</sub>-C<sub>10</sub>) triglycerides, are Labrafac® CM 6, Labrafac® CM 8, Labrafac® CM 10, Labrafac® CM 12, and Labrasol® (Labrafac® CM 14). Of these, especially preferred and regarded as the best mode of carrying out the present invention is the polyglycolyzed glyceride Labrafac® CM 10.

It is also expected that analogs and derivatives of the above polyglycolyzed glycerides will be identified which are suitable for use in the compositions and methods of the present invention. To the extent that these analogs and derivatives are similar in structure to or are readily obtained by chemical modification of the polyglycolyzed glycerides, while substantially retaining the physical properties of the polyglycolyzed glycerides, such analogs and derivatives are intended to be included among the compositions and methods of the present invention.

It is expected that the compositions and methods of the invention will be suitable for the administration of a wide variety of peptide and non-peptide drugs. Examples of peptides which may be delivered in this fashion are interferons and other macrophage activation factors, such as lymphokines, muramyl dipeptide (MDP),  $\gamma$ -interferon, and interferons  $\alpha$  and  $\beta$ , and related antiviral and tumoricidal agents; opioid peptides and neuropeptides, such as enkephalins, endorphins and dynorphins, and related analgesics; renin inhibitors including new-generation anti-hypertensive agents; cholecystokinins (CCK analogs) such as CCK, ceruletide and eledoisin, and related cardiovascular- and CNS-targeting agents; leukotrienes and prostaglandins, such as oxytocin, and related antiinflammatory, oxytocic and abortifacient compounds; erythropoietin and analogs thereof, as well as related haematinics; LHRH analogs, such as leuprolide, buserelin and nafarelin, and related down-regulators of pituitary receptors; parathyroid hormone and other growth hormone analogs; enzymes, such as DNase, catalase and  $\alpha$ -1 antitrypsin; immunosuppressants such as cyclosporin; GM-CSF and other immunomodulators; and insulin. Such peptides or peptide analogs are frequently not well-absorbed when given orally. A preferred medicament for use in the formulations of the present invention is leuprolide acetate.

Examples of non-peptides which may readily be delivered using the compositions and methods of the present invention are beta-agonists, such as isoproterenol, albuterol, isoetherine and metoproteronol, and related anti-asthmatics; steroids, such as flunisolide, and similar anti-asthmatics; cholinergic agents, such as cromolyn, and related anti-asthmatics; and  
5 5-lipoxygenase inhibitors, such as zileuton and the hydroxyurea compound described above, and related leukotriene inhibitors. Such non-peptides may lend themselves to oral administration, but when given by inhalation are found to produce rapid reversal of bronchoconstriction in cases of allergic airway disease and asthma. Also, these compounds may be administered more frequently as MDI formulations than when given orally.

10 The medicaments useful in the compositions of the present invention include not only those specifically named above, but also where appropriate the pharmaceutically acceptable salts, esters, amides and prodrugs thereof. By "pharmaceutically acceptable salts, esters, amides and prodrugs" is meant those carboxylate salts, amino acid addition salts, esters, amides and prodrugs of a compound which are, within the scope of sound medical judgement,  
15 suitable for use in contact with with the tissues of humans and lower animals with undue toxicity, irritation, allergic response and the like, commensurate with a reasonable benefit/risk ratio and effective for their intended use. In particular, the term "salts" refers to the relatively non-toxic, inorganic and organic acid addition salts of a medicinal compound. These salts can be prepared *in situ* during the final isolation and purification of the compound or by separately  
20 reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate and laurylsulphonate  
25 salts and the like. These may include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium and the like, as well as nontoxic ammonium, quaternary ammonium and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine and the like. (See, for example S. M. Berge, et al.,  
30 "Pharmaceutical Salts," J. Pharm. Sci., 66:1-19 (1977), incorporated herein by reference.)

Examples of pharmaceutically acceptable, non-toxic esters of a compound include (C<sub>1</sub>-to-C<sub>6</sub> alkyl) esters wherein the alkyl group is a straight or branched chain. Acceptable esters also include (C<sub>5</sub>-to-C<sub>7</sub> cycloalkyl) esters as well as arylalkyl esters such as, but not limited to, benzyl; (C<sub>1</sub>-to-C<sub>4</sub> alkyl) esters are preferred..

35 Examples of pharmaceutically acceptable, non-toxic amides of medicinal compounds include amides derived from ammonia, primary (C<sub>1</sub>-to-C<sub>6</sub> alkyl) amines and secondary



(C<sub>1</sub>-to-C<sub>6</sub> dialkyl) amines wherein the alkyl groups are straight or branched chain. In the case of secondary amines the amine may also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom. Amides derived from ammonia, (C<sub>1</sub>-to-C<sub>3</sub> alkyl) primary amides and (C<sub>1</sub>-to-C<sub>2</sub> dialkyl) secondary amides are preferred. Amides of the compounds of the invention may be prepared according to conventional methods.

The term "prodrug" refers to compounds that are rapidly transformed *in vivo* to yield the parent medicinal compound, as for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems", Vol 14 of the A.C.S. Symposium Series, and in *Bioreversible Carriers in Drug Design*, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press (1987), both of which are incorporated herein by reference.

When used in the above compositions, a therapeutically effective amount of a medicament of the present invention may be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester or prodrug form. By a "therapeutically effective amount" of a medicament is meant a sufficient amount of the compound to obtain the intended therapeutic benefit, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the medicaments and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgement. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.

The total daily doses of the medicaments contemplated for use with this invention, and consequently the concentrations by weight of the medicaments in the respective compositions, may vary widely. In the case of an LHRH analog, such as leuprolide acetate, the intended daily dose may range from about 0.01 to about 5 mg/day; accordingly, where an aerosol inhaler is to be used several times a day with a discharge volume of between about 5 and about 250  $\mu$ L, the concentration of medicament will be between about 0.2 and about 20 mg/mL. Similarly, in the case of a 5-lipoxygenase inhibitor expected to be administered in a daily dose

ranging from about 0.01 to about 10 mg/kg/day, the concentration will be between about 0.001 and about 100 mg/mL. Of course, medicament concentrations outside of these ranges may also be suitable, where different potencies, dosing frequencies and discharge volumes are used.

5           The compositions of the invention may be prepared by combining the polyglycolyzed glyceride with a medicament which has been milled or otherwise reduced to a desired particle size, and placing the mixture in a suitable aerosol container or vial. After sealing the container, an aerosol propellant is introduced and the system is agitated to fully blend the ingredients. Alternatively, the polyglycolyzed glyceride and medicament may be milled together, either  
10       before or after addition of propellant. In some instances, it may be necessary to wet-mill the medicament in a closed system, as for example under temperature and pressure conditions which permit the medicament to be milled while mixed with a liquid-phase aerosol propellant. It is expected that, for any particular combination of medicament, propellant and polyglycolyzed glycerides, the ideal order of addition of ingredients and the conditions under  
15       which they are to be combined may readily be determined.

          The compositions and methods of the present invention will be better understood in connection with the following examples, which are intended as an illustration of and not a limitation upon the scope of the invention. Both below and throughout the specification, it is  
20       intended that citations to the available literature are expressly incorporated by reference.

#### Example 1

##### Characterization of Labrafac® CM 10

25           Labrafac® CM 10 comprises medium chain (C<sub>8</sub>-C<sub>10</sub>) polyglycolyzed glycerides, and has a Hydrophilic Lipophilic Balance value of about 10. It is an oily liquid with a faint odor and a color on the Gardner Scale of <5. Specific gravity at 20°C is 1.000-1.040. Refractive Index at 20°C is 1.430-1.485. Viscosity at 20°C (mPa.s) is 20-90. Solubility at 20°C: ethanol (95% in H<sub>2</sub>O), very soluble; chloroform, very soluble; methylene chloride, very soluble;  
30       water, dispersible; mineral oil, insoluble; vegetable oil, very soluble. Chemical characteristics: Acid Value (mg KOH/g), <2.00; Saponification Value (mg KOH/g), 160-200; Iodine Value (g I<sub>2</sub>/100 g), <2; Hydroxyl Value (mg KOH/g), 115-155; Peroxide Value (meq O<sub>2</sub>/kg), <12.5; Alkaline Impurities (ppm MaOH), <80; Water Content (%), <1.00; Free Glycerol Content (%), <3.0; 1 Monoglycerides Content (%), <15.0; Sulphated Ashes (%), <0.10; Heavy Metals  
35       (ppm Pb), <10.

Example 2Physical Stability of MDI Formulations Containing Labrafac®

5 A determination of the effect of Labrafac® CM 10 on the physical stability of several MDI formulations prepared with HFA-134a was conducted as follows: Labrafac® CM 10 (Gattefossé, Westwood, New Jersey) and each of the drugs being formulated were combined in the amounts shown in appropriate transparent aerosol containers (vials). (Leuprolide acetate and its preparation are described in United States Patent No. 4,005,063, issued January 25, 1977, which is incorporated herein by reference.) Additionally, to some of the vials was added  
10 the sweetener aspartame (Nutrasweet Corp., Skokie, Illinois) in an amount to produce a final concentration of 0.2% by weight. The vials were crimped and charged with approximately 10 mL of HFC-134a and agitated to blend the ingredients. The dispersion quality in each preparation was evaluated visually after 24 hours using the following criteria:

Poor:	Phase separation; top phase clear, bottom phase containing solids
Fair:	Partial phase separation; cloudiness in the top phase
Good:	Grainy appearance; no phase separation
Excellent:	Milky homogeneous appearance; no phase separation

15

Results of these tests are shown below in Tables 1 and 2. The data obtained show that the formulations of the present invention maintain a high degree of dispersion even after 24 hours. By comparison, control formulations of each of the test compounds (which were prepared without polyglycolized glyceride) are seen to have unacceptable dispersion quality  
20 (which was evident in each case after less than 30 seconds).

Table 1  
Dispersion Quality of Leuprolide Acetate in HFA-134a

<u>Leuprolide Concentration</u>	<u>Labrafac® CM 10 Concentration</u>	<u>Aspartame Concentration</u>	<u>Dispersion Quality (24 Hours)</u>
1%	0.05%	0.00%	Good
1%	0.10%	0.00%	Good
1%	0.30%	0.00%	Good
1%	0.50%	0.00%	Good
1%	0.20%	0.01%	Good
1%	0.20%	0.05%	Good
1%	0.20%	0.10%	Good
1%	0.20%	0.20%	Good

5

Table 2  
Dispersion Quality of Cyclosporin A in HFA-134a

<u>Cyclosporin A Concentration</u>	<u>Labrafac® CM 10 Concentration</u>	<u>Dispersion Quality (24 Hours)</u>
2.5%	0.00%	Poor
2.5%	0.05%	Good
2.5%	0.10%	Good
2.5%	0.15%	Good
2.5%	0.25%	Good

10

A further comparison of various dispersants was conducted as before. The results, shown in Table 3, demonstrate that dispersion quality of the formulation of the present invention, after 24 hours, is superior to that obtained using other known dispersants.

Table 3  
Dispersion Quality of 25 mg/mL Cyclosporin A in HFA-134a

<u>Sample No.</u>	<u>Dispersant 2.5 mg/mL</u>	<u>Dispersion Quality (24 Hours)</u>
1	Span 85	Poor
2	Oleic Acid	Poor
3	Lecithin	Fair
4	Span 20	Poor
5	Decanesulfonic Acid	Good
6	Sodium Lauryl Sulfate	Good
7	Cholesterol	Good
8	Vitamin E	Good
9	Labrafac	Excellent
10	Ascorbic Acid	Good

5

Example 3  
Preparation of MDI Formulations for Performance Testing

10 For each test formulation, between 7 and 12 g of glass beads were placed into a suitable glass aerosol container (vial), along with 100 mg to 250 mg drug, Labrafac® CM 10 and Aspartame in the amounts needed to produce the desired final concentrations. The vials were crimped shut with valves having delivery values (volumes per spray) of either 50  $\mu$ L or 100  $\mu$ L, and then charged with 10 mL of HFA-134a propellant. The filled vials were then shaken for 24 hours to mill and disperse the drug, after which testing was carried out *in vitro* or *in vivo* as described below.

15

Example 4  
Uniformity of MDI Delivery of Compositions Containing Leuprolide

20 Delivery uniformity and physical stability of the compositions of the invention containing the Leuprolide were tested as follows: Each vial was shaken and its valve primed by aerosolizing 5 times in succession, after which the vial was weighed. The valve of each vial was then actuated ten times, followed by another weighing. This process was repeated until shot weights had been determined for 100 sprays.

The shot weight data, shown below in Table 4, demonstrate the uniformity with which the compositions of the present invention are delivered by a MDI device.

Table 4

Shot Weight Data for Leuprolide Aerosol (10 mg/mL)  
Containing 0.2% Labrafac® CM 10 and 0.05% Aspartame

<u>Sprays</u>	<u>Total Can 1 (grams)</u>	<u>Total Can 2 (grams)</u>
1-10	0.61	0.61
11-20	0.60	0.62
21-30	0.61	0.61
31-40	0.60	0.62
41-50	0.64	0.63
51-60	0.62	0.59
61-70	0.63	0.61
71-80	0.61	0.61
81-90	0.60	0.61
91-100	0.60	0.62

Example 5

Uniformity of MDI Delivery of Compositions Containing Cyclosporin A

Delivery uniformity and physical stability of the compositions of the present invention containing cyclosporin A were tested as follows: Cyclosporin A was formulated as described above to produce a composition containing 25 mg/ml cyclosporin and either 3 or 5 mg/ml Labrafac® CM 10 as shown. Each vial was shaken and its valve (delivering 0.1 ml per spray) was primed by aerosolizing 5 times in succession, after which the vial was weighed. The valve of each vial was then actuated ten times, followed by another weighing. This process was repeated until shot weights had been determined for 70 sprays.

The drug content uniformity, shown in Figure 1, shows the amount of drug delivered as mg per 10 sprays plotted against the number of sprays. These results demonstrate the uniformity with which the compositions of the present invention are delivered by a MDI device, in that all values through 45 sprays fall within the desired target range. Only after 45 sprays (that is, during "tail-off") do the values fall below the lower target.

### Example 6

#### Dosimetry Reproducibility of Compositions Containing Cyclosporin A

5        Dosimetry reproducibility of the compositions of the present invention containing Cyclosporin A were tested as follows: Cyclosporin A was formulated as described above to produce a composition containing 25 mg/ml cyclosporin and 3 mg/ml Labrafac® CM 10 in HFC-134a. Each vial was shaken and its valve (delivering 0.1 ml per spray) was primed by aerosolizing 5 times in succession. Then, on Day 0, the valve of each vial was submerged in a beaker of methanol and actuated five times, after which the amount of drug delivered was assayed using quantitative HPLC. This process was repeated on Days 3, 7, 10 and 12 for each vial.

10        The results, shown in Figure 2, shows the amount of drug delivered on each of the sampling dates for each of three test formulations. These results demonstrate a tight correlation with the target dose, and demonstrate excellent dose reproducibility achieved by the present invention.

### Example 7

#### Bioavailability of MDI Compositions Containing Labrafac®

20        Using a test preparation of leuprolide containing 10 mg/mL drug, 0.2% (by weight) Labrafac® CM 10 and 0.05% (by weight) aspartame in HFC-134a propellant, bioavailability of aerosol-delivered drug was compared to that of an aqueous control formulation delivered intravenously (IV) and a CFC formula containing 0.5% sorbitan trioleate (SPAN 85, NDA commercial grade). Three or four tracheostomized beagle dogs (two-year-old females, Marshall Labs) were used for each group. To the dogs in the IV group, 0.1 mg/kg drug was given intravenously over a 1 minute period as a 1 mg/mL solution in 60% PEG 400 (polyethylene glycol, Union Carbide Co., Institute, W. Virginia) in water. To the dogs in the aerosol groups, 0.3 mg/kg of drug was administered by sprays of the test formulations delivered into the trachea. Blood samples were collected at specified time intervals and analyzed for drug concentration using high performance liquid chromatography.

30        The results of these studies, shown below in Table 5, demonstrate that drugs are effectively administered using the MDI formulations of the present invention. In particular, bioavailability of the aerosolized drug over a 24-hour period was ~95% that of the same amount delivered intravenously, based on area-under-curve (AUC) calculations. Net bioavailability, when corrected for non-absorptive loss of drug (as for example due to loss in

the dosing device, inertial impaction of the spray in the trachea, and expulsion with exhaled air), exceeded 90% of that obtained using intravenous administration.

Table 5

Comparison of Intravenous and MDI Delivery of Leuprolide

<u>Formula</u>	<u>Dose of Leuprolide</u>	<u>No. of Dogs</u>	<u>AUC (CV) min (ng/mL)</u>	<u>Bioavailability (%)</u>
IV	0.1 mg/kg	3	17651 (0.2)	100
CFC	0.3 mg/kg	4	45693 (0.4)	81
HFC	0.3 mg/kg	4	50479 (0.4)	93

CFC Formula: 0.5% SPAN 85

HFC Formula: 0.2% Labrafac® CM 10, 0.05% aspartame

Example 8

Respirable Fraction of Leuprolide MDI Compositions Containing Labrafac®

Particle sizing was done by light scattering using a method based on the Fraunhofer optical diffraction principle. Particle size data on reference standard dispersions were collected by sweeping a total of two hundred times to insure that a representative, randomly oriented sample from all size classes had been measured. Samples prepared as aerosolized spray were measured for reference standards and formulations of multiple lots of leuprolide and dextrose.

For all samples, the log-normal model was used for analyzing the distribution.

Respirable fraction (RF) measurements were made from the particle size distribution data. The term refers to the fraction of drug estimated from biophysical measurements to deposit in the peripheral zones of the lung. The respirable fraction is the amount of drug in mg which is less than 4.7  $\mu$ m in diameter divided by the total amount of drug sprayed in mg; this fraction is multiplied by 100 to give the RF as a percentage.

The test formulation was a leuprolide aerosol with a concentration of 10 mg/mL containing 0.2% (by weight) Labrafac® CM 10 and 0.05% (by weight) aspartame. The particle size was plotted against the percentage at or below a given particle size. The results are shown in Figure 3. A favorable respirable fraction has a particle size distribution such that a large portion of the discharge reaches the alveoli where absorption takes place, and thus producing high lung deposition efficiencies; the ideal respirable range is between 0.5  $\mu$ m and



4.7  $\mu\text{m}$ . The data show that 55% of the formulation falls within the respirable range; this can be compared with many formulations of the prior art which have only 25% falling within the range.

5

It is understood that the foregoing detailed description and accompanying examples are merely illustrative and are not to be taken as limitations upon the scope of the invention, which is defined solely by the appended claims and their equivalents. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications, including without limitation those relating to the substituents, means of preparation and/or methods of use of the invention, may be made without departing from the spirit and scope thereof.

10

What is claimed is:

1. A pharmaceutical composition for aerosol delivery comprising a medicament, a non-chlorofluorocarbon propellant, and a polyglycolized glyceride.
2. A pharmaceutical composition according to Claim 1 wherein the propellant is a halogenated alkane.
3. A pharmaceutical composition according to Claim 2 wherein the propellant is selected from the group consisting of HFC-134a and HFC-227ea.
4. A pharmaceutical composition according to Claim 1 wherein the polyglycolized glyceride has a Hydrophilic Lipophilic Balance (HLB) of between about 6 and about 14.
5. A pharmaceutical composition according to Claim 2 wherein the polyglycolized glyceride is selected from the group consisting of Labrafac® CM 6, Labrafil® WL 2609 BS, Labrafac® CM 8, Labrafac® CM 10, Labrafil® M 10, Labrafil® NA10, Labrafac® CM 12, and Labrasol® (Labrafac® CM 14).
6. A pharmaceutical composition according to Claim 2 wherein the polyglycolized glyceride is present in a concentration of between about 0.002% and about 5% by weight.
7. A pharmaceutical composition according to Claim 2 wherein the polyglycolized glyceride is present in a concentration of between about 0.01% and about 1% by weight.
8. A pharmaceutical composition according to Claim 2 wherein the medicament is selected from the group consisting of LHRH analogs, 5-lipoxygenase inhibitors, immunosuppressants and bronchodilators.
9. A pharmaceutical composition according to Claim 2 wherein the medicament is selected from the group consisting of leuprolide acetate, Ac-D-2-Nal-D-4-CIPhe-D-3-Pal-Ser-N-MeTyr-D-Lys(Nic)-Leu-Lys(N-Isp)-Pro-D-Ala-NH<sub>2</sub>; cyclosporin A; albuterol and isoproterenol.
10. A pharmaceutical composition according to Claim 3 wherein the medicament is leuprolide acetate.

11. A pharmaceutical composition according to Claim 8 wherein the propellant is HFC-134a.
12. A pharmaceutical composition according to Claim 10 wherein the polyglycolized glyceride is present in a concentration of between about 0.01% and about 1% by weight.
13. A pharmaceutical composition according to Claim 9 comprising leuprolide acetate in a concentration between about 0.05% and about 5% by weight, Labrafac® in a concentration between about 0.01% and about 1% by weight, aspartame in a concentration between about 0.02% and about 0.5% by weight, and menthol in a concentration between about 0.01 and about 0.25% by weight.
14. A pharmaceutical composition according to Claim 9 comprising leuprolide acetate in a concentration between about 0.125% and about 0.5% by weight, Labrafac® in a concentration between about 0.1% and about 0.5% by weight, aspartame in a concentration between about 0.05% and about 0.2% by weight, and menthol in a concentration between about 0.025 and about 0.1% by weight.
15. A pharmaceutical composition according to Claim 9 comprising leuprolide acetate in a concentration of between about 0.5% and about 2% by weight, Labrafac® in a concentration of between about 0.2% and about 1% by weight, aspartame in a concentration of about 0.1% by weight, and menthol in a concentration of about 0.05% by weight.
16. A method of preparing a stable suspension of particles of a medicament in a liquid phase non-chlorofluorocarbon aerosol propellant, comprising the steps of
  - (a) combining the medicament, the propellant, and a polyglycolized glyceride in an amount sufficient to prevent aggregation of the particles to form a mixture, and
  - (b) agitating the mixture.
17. A method according to Claim 16 wherein the polyglycolized glyceride is added in an amount of between about 0.002% and about 5% by weight.
18. A method according to Claim 16 wherein the polyglycolized glyceride is added in an amount of between about 0.01% and about 1% by weight.

19. A method according to Claim 16 wherein the medicament is selected from the group consisting of LHRH analogs, 5-lipoxygenase inhibitors, immunosuppressants and bronchodilators.
20. A method according to Claim 19 wherein the propellant is a halogenated alkane.
21. A method according to Claim 16 wherein the propellant is selected from the group consisting of HFC-134a and HFC-227ea.
22. A method according to Claim 16 wherein the medicament is selected from the group consisting of leuprolide acetate, Ac-D-2-Nal-D-4-ClPhe-D-3-Pal-Ser-N-MeTyr-D-Lys(Nic)-Leu-Lys(N-Isp)-Pro-D-Ala-NH<sub>2</sub>; cyclosporin A; albuterol and isoproterenol.
23. A method according to Claim 16 wherein the polyglycolized glyceride is Labrafac® CM 10.

1/3




FIG. 1

2/3




FIG. 2




FIG. 3

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 95/10469

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K9/08 A61K47/14

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,93 18746 (ASTA MEDICA A.G.) 30 September 1993 see page 4, line 1 - page 7, paragraph 1 see page 12 - page 13; examples 1,3 ---	1-4,6-8, 11,16-21
X	EP,A,0 518 600 (SCHERING CORPORATION) 16 December 1992 see page 2, line 33 - line 43 see page 3, line 25 - page 4, line 41 see page 8; example 8 ---	1-4,6-9, 16-22
X	EP,A,0 561 166 (ASTA MEDICA A.G.) 22 September 1993 see page 4; example 1 see claim 1 ---	1-3,6,7, 16-18
	---	
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

4 January 1996

Date of mailing of the international search report

10. 01. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Boulois, D



# INTERNATIONAL SEARCH REPORT

In International Application No  
PCT/US 95/10469

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 518 601 (SCHERING CORPORATION) 16 December 1992 see page 4, line 34 - line 57 see page 5, line 23 - line 23 ---	1-4,8,9, 16
P,X	EP,A,0 656 206 (SCHERING CORPORATION) 7 June 1995 see page 8; example 8 ---	1-4,6-9, 16-22
A	US,A,3 288 824 (MAHLER E. ET AL) 29 November 1966 see column 4, line 45 - line 75 see column 7 - column 8; example 1 ---	1
A	EP,A,0 510 731 (ABBOT LABORATORIES) 28 October 1992 see the whole document ---	1
A	WO,A,92 00061 (FISONS PLC) 9 January 1992 see claims -----	1

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/ 10469

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.: 5  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
**PLEASE SEE ATTACHED SHEET!**
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

INCOMPLETE SEARCH

2. Obscurities,... etc.

Article 6 PCT (Obscurity): Apart from LABRAFAC® CM 10, described in example 1, and LABRASOL® and LABRAFIL® WL 2609BS, which are already registered products, the other products claimed in claim 5 could not be searched because their composition is unknown and because they are not described in the present application.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/10469

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9318746	30-09-93	DE-A- 4230876	23-09-93
		AU-B- 3745993	21-10-93
		CA-A- 2129855	18-09-93
		EP-A- 0630229	28-12-94
		FI-A- 944257	14-09-94
		HU-A- 68223	28-06-95
		JP-T- 7508506	21-09-95
		NO-A- 943305	07-09-94
		US-A- 5415853	16-05-95
		ZA-A- 9301907	06-10-93
EP-A-518600	16-12-92	AU-B- 2017592	12-01-93
		CA-A- 2111002	23-12-92
		CN-A- 1067578	06-01-93
		CZ-A- 9302714	13-07-94
		EP-A- 0588897	30-03-94
		EP-A- 0656206	07-06-95
		EP-A- 0656207	07-06-95
		HU-A- 67449	28-04-95
		JP-T- 6511235	15-12-94
		NO-A- 934500	09-12-93
		OA-A- 9868	15-08-94
		WO-A- 9222288	23-12-92
		US-A- 5474759	12-12-95
EP-A-561166	22-09-93	AU-B- 3526193	23-09-93
		DE-A- 4305078	23-09-93
		JP-A- 6016539	25-01-94
		ZA-A- 9301875	06-10-93
EP-A-518601	16-12-92	AU-B- 2178992	12-01-93
		CA-A- 2111003	23-12-92
		CN-A- 1067579	06-01-93
		CZ-A- 9302713	13-07-94
		EP-A- 0587790	23-03-94
		EP-A- 0656205	07-06-95
		EP-A- 0653205	17-05-95
		HU-A- 67445	28-04-95
		JP-T- 6508149	14-09-94
		NO-A- 934499	09-12-93

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/US 95/10469

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-518601		OA-A- 9827 WO-A- 9222287	15-04-94 23-12-92
EP-A-656206	07-06-95	EP-A- 0656207 AU-B- 2017592 CA-A- 2111002 CN-A- 1067578 CZ-A- 9302714 EP-A- 0518600 EP-A- 0588897 HU-A- 67449 JP-T- 6511235 NO-A- 934500 OA-A- 9868 WO-A- 9222288 US-A- 5474759	07-06-95 12-01-93 23-12-92 06-01-93 13-07-94 16-12-92 30-03-94 28-04-95 15-12-94 09-12-93 15-08-94 23-12-92 12-12-95
US-A-3288824	29-11-66	DE-B- 1298976 FR-A- 1274354 GB-A- 847517	14-02-62
EP-A-510731	28-10-92	US-A- 4897256 US-A- 4851211 CA-A- 1300009 DE-A- 3785570 DE-T- 3785570 EP-A, B 0275404 JP-A- 63211237	30-01-90 25-07-89 05-05-92 27-05-93 18-11-93 27-07-88 02-09-88
WO-A-9200061	09-01-92	AU-B- 8055691 CA-A- 2085884 EP-A- 0536235 IL-A- 98666	23-01-92 30-12-91 14-04-93 12-04-94